Authors
Latest:
UTI vaccine shows efficacy, safety in men and women"Overall, this vaccine is safe in the long term and our participants reported having fewer UTIs that were less severe," says Bob Yang, MBBS, FRCS.
Latest:
Strategies to bridge gender disparities in AAS and citations in the oncology literatureOne key approach is to increase the representation of women on editorial boards of journals and as reviewers.
Latest:
Update on advanced imaging in prostate cancerAdvances allow for more accurate detection of metastatic disease.
Latest:
Baseline 68Ga-PSMA-11 PET/CT parameters can predict response to 177Lu-PSMA-617"For every 1 unit increase in whole body tumor SUVmean, there was a 12% decrease in the risk of an rPFS event and a 10% decrease in the risk of death," says Phillip H. Kuo, MD, PhD, FACR.
Latest:
Optimizing Care Collaboration in Advanced Prostate CancerExplore strategies for seamless coordination between urologists and medical oncologists to ensure uninterrupted, patient-focused care in prostate cancer treatment.
Latest:
Investigators highlight real-world data on nadofaragene firadenovec in NMIBC"At 3 months, those patients had a 79% complete response rate, which was durable in 74% at 6 months and 60% at 9 months," says Jacob A. Moyer, BS.
Latest:
Medical software should be chosen based on your practice’s life cycle stageAt each stage, health care providers have different priorities and goals, and the choice of medical software solutions should be made accordingly.
Latest:
Gal Wald, MD: BCG plus gemcitabine shows early efficacy in NMIBC"Overall, our trial shows promising early oncological efficacy with a favorable toxicity profile," says Gal Wald, MD.
Latest:
The current state of adjuvant radiotherapy post prostatectomy: 3 take-home messages"If your practice does not closely monitor patients and send them for early salvage radiotherapy when their PSA is 0.1 or 0.2 ng/mL, it is likely that adjuvant radiotherapy is superior," Daniel E. Spratt, MD, writes.
Latest:
Presentation, diagnosis, and management of a rare case of urachal adenocarcinoma"Urachal carcinoma is a rare and aggressive malignancy. The low incidence of the disease results in limited large-scale clinical trials that could provide standardized guidelines for its diagnosis and management," write Christopher Pieczonka, MD, and Peter Fioramonti, BS.
Latest:
Study: Few surgical programs share parental leave policies onlinePolicy availability varied by specialty, with urology leading in program-specific policies—yet still only at 11%.
Latest:
Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert PanelPanelists discuss the critical unmet need for more personalized treatment in non–muscle-invasive bladder cancer (NMIBC), emphasizing the role of biomarkers, emerging modalities like radiation, and optimized therapy sequencing to improve outcomes, as current approaches still leave many patients at risk of relapse despite expanding therapeutic options.
Latest:
Subgroup data sustain enzalutamide PFS benefit in nmCRPCNo new safety signals were reported with the androgen receptor pathway inhibitor.
Latest:
Continued Advances and Unmet Needs in PSMA-Based Imaging for Prostate CancerExperts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.
Latest:
Exploring the potential role of ctDNA as a biomarker in kidney cancer"The take-home point from our study of these 92 patients is that in metastatic kidney cancer, there's a high concordance [between] MRD positivity and patients having progressive disease," says Alan Tan, MD.
Latest:
FDA testosterone labeling changes: How will they affect prescribing?"In a practice like mine, where approximately 30% of the practice is low testosterone, it'll have actually very little negative effect," says John P. Mulhall, MD.
Latest:
New study uncovers how prostate cancer becomes deadly and offers hope for new treatmentsA first-of-its kind study led by Emory researchers uncovered how prostate cancer transforms into its most lethal form — and identified a promising new treatment strategy.
Latest:
Minimizing incontinence after radical prostatectomy: Lessons learned"I've worked in 3 different countries, I've seen dozens of people doing robotic radical prostatectomy...so my current practice is kind of a “best of” what I have seen and learned," says Ricardo Soares, MD.
Latest:
Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.
Latest:
Neoadjuvant combo boosts MRD negativity rates in high-risk prostate cancerAdding apalutamide to the hormone therapy degarelix in the neoadjuvant setting increased the likelihood of achieving minimal residual disease negativity in patients with high-risk prostate cancer after radical prostatectomy.
Latest:
Physician Commentary: Do EHR upgrades really enhance patient care?"Clinicians, now more than ever, have many data entry duties. The clinical encounter’s efficiency is dictated by the ease of the EHR," write Jesse D. Bracamonte, DO, FAAFP, and Michael Underhill, DO.
Latest:
Case review: An incidentally discovered renal massAn expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.
Latest:
Expert explains how to fully optimize EHRsRecent advances in technology make it possible to access and harness the vast amounts of clinical data EHRs have produced.
Latest:
Exploratory analysis identifies blood-based biomarkers that may predict treatment outcomes in urothelial carcinomaThe exploratory analysis may have showcased the benefit of testing for tertiary lymphoid structures.
Latest:
Current and Emerging Treatment Landscape of mHSPCJack Andrews MD; Eugene Cone, MD; and Arash Rezazadeh, MD, discuss how metastatic hormone-sensitive prostate cancer presents clinically, explore current treatment standards including combination therapies, evaluate emerging data from the ARANOTE trial on darolutamide efficacy, consider quality of life factors in treatment selection, and examine how novel therapeutic approaches may reshape future care pathways.
Latest:
Front-line maintenance with avelumab found efficacious for locally advanced, metastatic mUCThe real-world data were presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Latest:
Amy Krambeck, MD, on considerations for building clinical programs in endourologyAmy E. Krambeck, MD, discusses how to define success and how to determine the optimal timing for adding on a new partner.
Latest:
Expert highlights the latest radiotherapy developments in prostate cancer“As the ability to target improved, what we really clearly saw was the idea that perhaps a treatment course could be shortened significantly, and that the term hypofractionation became commonly applied to men with prostate cancer,” said Walter J. Curran Jr, MD, FACR, FASCO.
Latest:
Physician Burnout: Assessing and addressing its impact on your family“A physician struggling under an unbearable weight of emotions, or going to work feeling like they are enduring emotional trauma can have trickle down emotional effects on family members,” writes physician and US Navy veteran Caitlin Delaney, MD.
Latest:
Ava Saidian, MD, on improving female representation in bladder cancer trials“Women not only tend to present with more aggressive disease, but they also have a higher probability of having what we call variant histology, so non-urothelial carcinoma,” says Ava Saidian, MD.
